Blood loss during a surgical procedure is inevitable, its reduction is a key factor for
surgical success. Also, to avoid progress to severe complications like hemodynamic
decompensation, cardiac arrest or the need to blood transfusions. According to the Center for
Disease Control (CDC), there is a usage of more than 17 million transfused blood products
units per year. Blood transfusion is a convenient technique for reposition of blood during
major bleed, but it involves several probable complications like anaphylaxis, bloodborne
infections and others. Consequently, meticulous hemostasis during surgery is crucial to
diminish blood loss.
Hemostatic agents play a pivotal role during surgical time. Amongst them topical,
energy-based and systemic agents are the vast majority. Tranexamic acid (TXA) is a lysine
synthetic derivate that inhibits fibrinolysis by blocking the 5 lysine-binding sites to
plasminogen. It has been used in clinical practice since 1962 and become very popular after
2010 when the CRASH-2 study showed a decreased risk of death in trauma patients.
Tranexamic acid use is widely extended among diverse surgical fields: orthopedics, cardiac
surgery and obstetrics. In plastic surgery it uses is limited mainly to craniofacial surgery
as a local agent. The aim of this trial is to show the efficacy of tranexamic acid as
hemostatic agent in liposuction and to compare its efficacy among different administration
routes.